FIELD: medicine; ophthalmology.
SUBSTANCE: invention is intended for the treatment of a disease, disorder or condition caused by Fuchs endothelial corneal dystrophy. A medicinal product containing an agent that inhibits the TGF-beta signal is used to treat a disease, disorder or condition caused by an abnormality of the extracellular matrix (ECM) in the corneal endothelium in a subject, where the disease, disorder or condition is due to Fuchs endothelial corneal dystrophy. The drug is eye drops.
EFFECT: use of the invention provides effective treatment of a disease, disorder or condition caused by Fuchs endothelial corneal dystrophy by inhibiting ECM overexpression.
6 cl, 9 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM | 2014 |
|
RU2712967C2 |
| DRUG CONTAINING mTOR INHIBITOR FOR TREATMENT OR PREVENTION OF EYE SYMPTOMS, DISORDERS, OR DISEASES, AND ITS USE | 2018 |
|
RU2782613C2 |
| COMPOSITION OR A METHOD COMPRISING (T)EW-7197 FOR THE TREATMENT OR PREVENTION OF CORNEAL ENDOTHELIAL DISEASES | 2018 |
|
RU2798396C2 |
| USING LAMININ IN CORNEAL ENDOTHELIAL CELL CULTURE | 2014 |
|
RU2704984C1 |
| MEANS FOR KIDNEY FIBROSIS TREATMENT | 2011 |
|
RU2635460C2 |
| AGENT FOR TREATING RENAL FIBROSIS | 2011 |
|
RU2711531C2 |
| IMPROVED DIFFERENTIATION METHOD | 2017 |
|
RU2772435C2 |
| ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION | 2007 |
|
RU2559532C2 |
| COMPOSITIONS AND METHODS OF PULMONARY HYPERTENSION TREATMENT | 2017 |
|
RU2748278C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
